Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

Figure 2

Percentages of patients with (A) American College of Rheumatology (ACR) 20%, 50%, or 70% improvement; (B) European League Against Rheumatism (EULAR) responses of at least ‘moderate’ and ‘good’; and (C) low disease activity (LDA) and disease remission (REM) defined as Simplified Disease Activity Index (SDAI) ≤11 and SDAI ≤3.3, respectively. Data are shown as observed values for all evaluable patients at each time point during long-term treatment with adalimumab (ADA). LO, last observation.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us